Approximately Ten Percent of Inpatients Receiving Antibiotic Treatment Have a Hospital-Acquired Bacterial Infection, According to Findings from Decision Resources and Arlington Medical Resources ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...

Timing of troughs Troughs should be obtained at steady state: approximately prior to the fifth dose IIB Optimal trough concentrations Should be >10 mg/l at a minimum to avoid development of ...

Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was investigated ...

COPENHAGEN, Denmark & BUFFALO GROVE, IL.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has ...

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...

Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...